Commission Bias Clinical

Commission bias is when people act too quickly and do something they think helps but may harm. In medicine, it means treating when waiting or watching might be better.

Commission bias denotes a proclivity for clinicians to intervene rather than observe, driven by perceived duty and risk aversion. It manifests as a systematic tendency to favor active treatments over conservative management despite uncertain net benefit.

A parent brings a child to a clinic with a mild sore throat. Even though the child most likely has a viral infection that will clear on its own, the doctor prescribes antibiotics anyway, reasoning that it's better to "do something" than risk the rare chance of a bacterial complication — even when guidelines recommend observation first.

A hospitalist evaluates a hemodynamically stable patient with an incidental finding of mild troponin elevation and non-specific ECG changes. Despite a pre-test probability of true acute coronary syndrome below 10% and HEART score of 2, the clinician orders urgent cardiology consultation, serial troponins, and initiates anticoagulation. The decision is driven by asymmetric weighting of false-negative costs (missed MI) over false-positive costs (bleeding risk, unnecessary catheterization), compounded by institutional audit protocols that track failure-to-treat events but not over-treatment events — a canonical weighting asymmetry producing intervention propensity well above the evidence-justified action threshold.

When clinicians fear missing something, they choose to do tests or treatments to be safe. That fear and the habit of acting cause more interventions than needed.

A contextual_analysis_systems__weighting_asymmetry arises when diagnostic uncertainty is overweighted toward commission, driven by asymmetric cost assignments to false negatives versus false positives and constrained by clinical protocols. Structural elements like guideline thresholds and audit processes skew decision weights, producing a biased action propensity.

Encourage pause and watchful waiting when safe and explain risks to patients. Use checklists to remind teams to consider observation first.

Implement decision thresholds and shared-decision tools that recalibrate action propensity toward conservative management where evidence supports it. Align incentives and audit metrics to penalize low-value interventions and reward appropriate observation.

Unnecessary procedures; Iatrogenic harm; Resource overuse

Pharmaceutical and device manufacturers can exploit commission bias by framing products as urgently necessary interventions, leveraging clinicians' asymmetric fear of under-treatment to drive adoption of marginally beneficial or unproven therapies. Hospital administrators and payers can structure audit metrics and performance dashboards to reward procedural volume, institutionally encoding commission bias into clinical workflows in ways that generate revenue while obscuring iatrogenic harm. Litigation threat narratives can be deliberately amplified to heighten perceived false-negative costs, weaponizing malpractice anxiety to shift clinician action thresholds toward high-value, billable interventions.

Clinicians can build resistance by explicitly pre-committing to watchful-waiting protocols with defined re-evaluation triggers, making omission a structurally equivalent option in decision frameworks rather than a default non-choice. Institutional audit systems should be recalibrated to flag and penalize low-value interventions alongside missed diagnoses, creating symmetric accountability for both commission and omission. Regular case review using decision threshold tools and shared decision-making training helps recalibrate individual action propensity by surfacing the asymmetric cost assignments that drive over-intervention.